Drug intelligence / Profile preview

carboplatin + paclitaxel + talactoferrin

Development stage: Unknown
Lead developer: Agennix
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of carboplatin, paclitaxel, and talactoferrin (recombinant human lactoferrin). This combination was investigated for the treatment of non-small cell lung cancer (NSCLC). In Phase II trials, adding talactoferrin to standard carboplatin/paclitaxel chemotherapy showed improved response rates and trends toward longer progression-free survival and overall survival with fewer adverse events compared to carboplatin/paclitaxel alone.

Other names: carboplatin + paclitaxel + recombinant human lactoferrincarboplatin + paclitaxel + rhLFcarboplatin + paclitaxel + talactoferrin alfa

Targets

DNA

Beyond the preview

Go deeper on carboplatin + paclitaxel + talactoferrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + paclitaxel + talactoferrin.

Explore the full profile